Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine and a related shot by the Serum Institute of India for use in this country with the first doses expected to arrive soon.
Cubresa is a privately held company based in Winnipeg and Boston that develops and markets preclinical PET and SPECT nuclear imaging products to allow researchers at leading hospitals, universities and pharmaceutical companies to non-invasively visualize and measure biochemical processes at the molecular level. Applications for our products include preclinical drug development and disease research in oncology, neurological, and cardiovascular areas. Our multimodal preclinical in vivo imaging products feature ultra-compact scanner footprints and excellent resolution, sensitivity and image quality.
Our vision is to improve human well-being by empowering researchers to better understand complex diseases and develop personalized therapies.